Record Nr.	UNINA9910369933103321
Titolo	Tumor Liquid Biopsies / / edited by Florence Schaffner, Jean-Louis Merlin, Nikolas von Bubnoff
Pubbl/distr/stampa	Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020
ISBN	3-030-26439-4
Edizione	[1st ed. 2020.]
Descrizione fisica	1 online resource (VI, 368 p.)
Collana	Recent Results in Cancer Research, , 0080-0015 ; ; 215
Disciplina	616.994 616.994075
Soggetti	Oncology Pathology Cancer - Research Cancer Research
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references.
Nota di contenuto	Circulating Tumor Cells: Pathophysiology of Tumor Cell Release into the Circulation and characterization of CTC CTC enrichment technologies Genotyping of CTC :example Lung cancer CTC in Breast Cancer: a clinical approach Circulating Tumor DNA: Pathophysiology of ctDNA Release into the Circulation and its characterization Enrichment and Analysis of ctDNA ctDNA in Lung Cancer ctDNA in Breast Cancer ctDNA in Colorectal Cancer Dynamic Treatment Stratification using ctDNA Circulating Tumor RNA: Noncoding Tumor RNAs: Pathophysiology of Release and Techniques of Detection Circulating miRNAs as Biomarker in Cancer Plasma Subcompartments as Source for Tumor derived Biomarkers: Exosomes and Vesicles as Biomarker in Cancer Quantitative proteomic Analysis of Plasma in Cancer.
Sommario/riassunto	This book is a comprehensive guide to the techniques, clinical applications, and benefits of the different forms of liquid biopsy employed in patients with a variety of tumor types, including lung, breast and colorectal cancer. Offering detailed explanations, it discusses the how changes in tumors can be tracked using these

1.

cutting-edge technologies, which enable the detection and analysis of diverse circulating biomarkers: tumor cells, tumor DNA, tumor RNA (free or in exosomes), and fluid biomarkers identifiable by means of targeted proteomics. The use of such advanced technologies is enabling us to tackle questions and problems in a way that was not possible just a few years ago. We now have at our disposal an effective means of overcoming the problem of intratumor heterogeneity, which has limited the value of conventional biopsy approaches. As a consequence, oncology practice is about to change radically, toward truly personalized precision medicine. This book provides both clinicians and researchers with a thorough and up-to-date overview of progress in the field.